C. Heterozygous loss-of-function of glucokinase that raises the glucose threshold for beta-cell insulin secretion
Why this is correct
Glucokinase (GCK) acts as a glucose sensor in pancreatic beta cells and supports hepatic glucose phosphorylation. A heterozygous inactivating GCK variant raises the glycemic set point for insulin release, producing mild, stable fasting hyperglycemia from birth, often detected across successive generations. This is GCK-MODY, classically nonprogressive outside special circumstances such as pregnancy, and usually does not require glucose-lowering pharmacotherapy. The phenotype differs from progressive HNF1A/HNF4A-associated MODY.
Why each option is correct or incorrect
Type 1 autoimmune diabetes usually has progressive insulin deficiency and often islet autoantibodies rather than stable familial mild hyperglycemia.
Isolated renal glucosuria can occur at normal plasma glucose and does not account for the elevated fasting blood glucose.
Correct: impaired beta-cell glucokinase changes the glucose threshold needed to stimulate insulin secretion.
An overly active insulin receptor would favor increased glucose disposal and potentially hypoglycemia, not this mild familial hyperglycemia.
High-yield notes
- GCK-MODY: autosomal dominant, mild lifelong fasting hyperglycemia.
- Glucokinase serves as a beta-cell glucose sensor.
- Unlike many other monogenic diabetes forms, GCK-MODY often needs no pharmacologic treatment outside specific settings.
Three generations with stable mild hyperglycemia and negative antibodies strongly suggest GCK-MODY.
Do not generalize all MODY to the same therapy: HNF1A-MODY can be highly sulfonylurea responsive, whereas GCK-MODY typically is not.